呼吸窘迫综合征是一种复杂的炎症性疾病，定义为急性低氧血症和细胞浸润以及组织损伤（例如急性肺损伤）后弥漫性肺泡损伤。这种病理学中涉及的炎症过程是身体针对传染源和/或组织损伤的防御机制。然而，如果病情得不到逆转，它就会成为组织损伤的重要原因，有时会导致受影响器官的功能丧失。因此，有必要了解炎症的潜在机制，以及开发减少这些情况下炎症损伤的新治疗药物。芳基环己酮衍生物先前已在体外显示出与免疫调节能力相关的显着抗炎活性，并且可能是炎症起核心作用的治疗的良好候选者。脂多糖（LPS）诱导的急性肺损伤的小鼠模型。急性口服毒性的评估遵循经济合作与发展组织 (OECD) 指南 423。结果表明，所研究的分子可预防 LPS 引起的炎症。我们观察到，除了渗出物、髓过氧化物酶（MPO）活性、一氧化氮代谢物和促炎细胞因子（α肿瘤）分泌减少外，总白细胞和分化白细胞向支气管肺泡灌洗液（BALF）的迁移减少。坏死因子 [TNF-α]、白介素 6 [IL-6]、干扰素 γ [IFN-γ] 和单核细胞趋化蛋白 1 [MCP-1]）。最后，芳基环己酮没有表现出急性口服毒性的迹象（OECD 423）。结果证明了我们的假设，即芳基环己酮是开发新型安全抗炎药物的有前途的分子。© 2024 Société Française de Pharmacologie et de Thérapeutique 。约翰·威利出版

Respiratory distress syndrome is a complex inflammatory condition defined by the presence of acute hypoxemia and cellular infiltration with diffuse alveolar injury following a tissue injury, such as acute lung injury. The inflammatory process involved in this pathology is a defense mechanism of the body against infectious agents and/or tissue injuries. However, when the condition is not reversed, it becomes a significant cause of tissue damage, sometimes leading to loss of function of the affected organ. Therefore, it is essential to understand the mechanisms underlying inflammation, as well as the development of new therapeutic agents that reduce inflammatory damage in these cases. Aryl-cyclohexanone derivatives have previously shown significant anti-inflammatory activity linked to an immunomodulatory capacity in vitro and may be good candidates for therapies in which inflammation plays a central role.Was evaluated the anti-inflammatory capacity of a synthesized molecule aryl-cyclohexanone in the murine model of lipopolysaccharide (LPS)-induced acute lung injury. The assessment of acute oral toxicity follows the Organization for Economic Co-operation and Development (OECD) guideline 423.The results demonstrated that the studied molecule protects against LPS-induced inflammation. We observed a decrease in the migration of total and differential leukocytes to the bronchoalveolar lavage fluid (BALF), in addition to a reduction in exudation, myeloperoxidase (MPO) activity, nitric oxide metabolites, and the secretion of pro-inflammatory cytokines (alpha tumor necrosis factors [TNF-α], interleukin-6 [IL-6], interferon-gamma [IFN-γ], and monocyte chemoattractant protein-1 [MCP-1]). Finally, aryl cyclohexanone did not show signs of acute oral toxicity (OECD 423).The results prove our hypothesis that aryl-cyclohexanone is a promising molecule for developing a new, safe anti-inflammatory drug.© 2024 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.